PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28373423
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170413
LR  - 20170413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Apr
TI  - New and Old Genes Associated with Topotecan Resistance Development in Ovarian
      Cancer Cell Lines.
PG  - 1625-1636
AB  - BACKGROUND: Low effectiveness of chemotherapy in ovarian cancer results from
      development of drug resistance. Topotecan is a drug used as second-line
      chemotherapy for this cancer type. We analyzed development of topotecan
      resistance in ovarian cancer cell lines. MATERIALS AND METHODS: A
      chemosensitivity assay, MTT test, was performed to assess drug resistance.
      Quantitative polymerase chain reaction (Q-PCR) assays were performed to determine
      ABCB1, ABCG2, ALDH1A1, IFIH1, SAMD4 and EPHA3 gene expression. RESULTS: We
      observed dose-dependent responses to topotecan. In all topotecan-resistant cell
      lines an overexpression of ABCG2, IFIH1 and SAMD4 genes was observed. Expression 
      of ABCB1 gene was observed in one cell line. Expression of ALDH1A1 was
      up-regulated in A2780 and down-regulated in SKOV-3-resistant cell lines.
      Short-time exposure led to similar patterns of gene expression for the
      investigated genes. CONCLUSION: Expression of ABCG2 and ABCB1 genes plays the
      most important role in topotecan resistance. The role of other investigated genes
      seems to be complementary.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Klejewski, Andrzej
AU  - Klejewski A
AD  - Department of Nursing, Poznan University of Medical Sciences, Poznan, Poland
      [email protected]
AD  - Department of Obstetrics and Womens Dieseases, Poznan University of Medical
      Sciences, Poznan, Poland.
FAU - Swierczewska, Monika
AU  - Swierczewska M
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      Poznan, Poland.
FAU - Zaorska, Katarzyna
AU  - Zaorska K
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      Poznan, Poland.
FAU - Brazert, Maciej
AU  - Brazert M
AD  - Division of Infertility and Reproductive Endocrinology, Department of Gynecology,
      Obstetrics and Gynecological Oncology, Poznan University of Medical Sciences,
      Poznan, Poland.
FAU - Nowicki, Michal
AU  - Nowicki M
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      Poznan, Poland.
FAU - Zabel, Maciej
AU  - Zabel M
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      Poznan, Poland.
AD  - Department of Histology and Embryology, Wroclaw Medical University, Poznan,
      Poland.
FAU - Januchowski, Radoslaw
AU  - Januchowski R
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      Poznan, Poland.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (P-Glycoproteins)
RN  - 0 (Topoisomerase I Inhibitors)
RN  - 7M7YKX2N15 (Topotecan)
SB  - IM
MH  - ATP-Binding Cassette Transporters/genetics
MH  - Biomarkers, Tumor/*genetics
MH  - Cell Proliferation/*drug effects
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Ovarian Neoplasms/*drug therapy/*genetics/pathology
MH  - P-Glycoproteins/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Topoisomerase I Inhibitors/pharmacology
MH  - Topotecan/*pharmacology
MH  - Tumor Cells, Cultured
OTO - NOTNLM
OT  - *Ovarian cancer
OT  - *drug transporters
OT  - *new genes
OT  - *topotecan resistance
EDAT- 2017/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/02/22 [received]
PHST- 2017/03/14 [revised]
PHST- 2017/03/15 [accepted]
AID - 37/4/1625 [pii]
AID - 10.21873/anticanres.11493 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Apr;37(4):1625-1636.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>